Skip to main content

Loading market data...

LLY

Eli Lilly and Company

NYSE • United states

$1,273.57

-$10.09

(-0.79%)

Source: Yahoo Finance · Quote time Oct 21, 2026 18:50 GMT+0000

Management
Credibility
Score

Eli Lilly and Company (LLY)

Unavailable

Quotes may be delayed

$1.20T

Market Cap

1,073,864

Volume

44.9

P/E Ratio

0.52%

Div Yield

Eli Lilly and Company Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: LILLY CORPORATE CTR, INDIANAPOLIS, IN
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

19 Oct 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Eli Lilly and Company.

17 Oct 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Eli Lilly and Company.

5 Aug 2026

Eli Lilly and Company filed Form 10-Q

Eli Lilly and Company submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

5 Aug 2026

Eli Lilly and Company reported Operating or financial results

Eli Lilly and Company filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

31 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Eli Lilly and Company.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$8.95B

Total assets (USD)$142.28B

Shareholders' equity (USD)$33.88B

Long-term debt (USD)$47.86B

Debt due within a year (USD)$7.05B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B
PM - Philip Morris International Inc.	$197.46 Yahoo Finance	$307.76B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$22.97B	Unavailable	$7.10B	$7.94	10-Q · 5 Aug 2026
Q1 2026	$19.80B	Unavailable	$7.40B	$8.26	10-Q · 30 Apr 2026
Q4 2025	$19.29B	Unavailable	$6.64B	Unavailable	10-K · 12 Feb 2026
Q3 2025	$17.60B	Unavailable	$5.58B	$6.21	10-Q · 30 Oct 2025
Q2 2025	$15.56B	Unavailable	$5.66B	$6.29	10-Q · 7 Aug 2025
Q1 2025	$12.73B	Unavailable	$2.76B	$3.06	10-Q · 1 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $1,370.95

7.6% upside potential

📈

Strong Buy

Unavailable

👍

Buy

20

⏸️

Hold

2

📉

Sell

1

23 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 18:50 UTC Targets range 940.00–1,600.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

19

Oct 2026

Sulzberger Gabrielle

Director

Grant or award

$1,240.34 per share

4 shares

19

Oct 2026

LUCIANO JUAN R

Director

Grant or award

$1,240.34 per share

13 shares

19

Oct 2026

Fyrwald J Erik

Director

Grant or award

$1,240.34 per share

8 shares

19

Oct 2026

Alvarez Ralph

Director

Grant or award

$1,240.34 per share

10 shares

21

Sep 2026

Sulzberger Gabrielle

Director

Grant or award

$1,164.89 per share

4 shares

21

Sep 2026

LUCIANO JUAN R

Director

Grant or award

$1,164.89 per share

14 shares

21

Sep 2026

Fyrwald J Erik

Director

Grant or award

$1,164.89 per share

9 shares

21

Sep 2026

Alvarez Ralph

Director

Grant or award

$1,164.89 per share

11 shares

Top Shareholders

Blackrock, Inc.

93,114,973 shares

26.101% change

6/30/2026

Lilly Endowment Inc

90,066,978 shares

-0.343% change

9/30/2026

Vanguard Group Inc

82,119,557 shares

-0.189% change

12/31/2025

Vanguard Capital Management Llc

65,276,117 shares

0.235% change

6/30/2026

Pnc Financial Services Group, Inc.

51,322,720 shares

-0.012% change

6/30/2026

State Street Corp

44,502,808 shares

21.082% change

6/30/2026

Fmr Llc

28,466,977 shares

-14.238% change

6/30/2026

Geode Capital Management, Llc

27,244,167 shares

19.442% change

6/30/2026

Vanguard Portfolio Management Llc

24,965,667 shares

19.014% change

6/30/2026

Capital Research Global Investors

20,873,140 shares

-15.262% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 18:50 UTC· 11 hours ago

Research coverage and investment tools

Eli Lilly and Company (LLY) is a stock listed on the New York Stock Exchange in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$1,273.57 on 21 Oct 2026. That is 93% of the way from its 52-week low of US$793.82 to its 52-week high of US$1,311.75. It paid US$6.69 a share in dividends over the last 12 months, a dividend yield of 0.52%. The latest ex-dividend date on file is 14 Aug 2026. Its market capitalisation was US$1.2 trillion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$22.97B	Unavailable	$7.10B	$7.94	—	—	—	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$19.80B	Unavailable	$7.40B	$8.26	—	—	—	10-Q · 30 Apr 2026 (opens in a new tab)
Q4 2025	$19.29B	Unavailable	$6.64B	Unavailable	—	—	—	10-K · 12 Feb 2026 (opens in a new tab)
Q3 2025	$17.60B	Unavailable	$5.58B	$6.21	—	—	—	10-Q · 30 Oct 2025 (opens in a new tab)
Q2 2025	$15.56B	Unavailable	$5.66B	$6.29	—	—	—	10-Q · 7 Aug 2025 (opens in a new tab)
Q1 2025	$12.73B	Unavailable	$2.76B	$3.06	—	—	—	10-Q · 1 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/5/2026	$8.38	$6.01	+39.4%
Mar 2026	4/30/2026	$8.55	$7.06	+21.1%
Dec 2025	2/4/2026	$7.54	$6.99	+7.9%
Sep 2025	10/30/2025	$7.02	$6.02	+16.6%

Cash and equivalents: $8.95B
Total assets: $142.28B
Shareholders' equity: $33.88B
Long-term debt: $47.86B
Debt due within a year: $7.05B

SCHEDULE 13G/A · 19 Oct 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Eli Lilly and Company.
SCHEDULE 13D · 17 Oct 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Eli Lilly and Company.
10-Q · 5 Aug 2026

Eli Lilly and Company filed Form 10-Q (opens in a new tab)

Eli Lilly and Company submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 5 Aug 2026

Eli Lilly and Company reported Operating or financial results (opens in a new tab)

Eli Lilly and Company filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
SCHEDULE 13D · 31 Jul 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Eli Lilly and Company.

Insider	Date	Transaction	Shares	Average price	Filing
Sulzberger Gabrielle Director	19 Oct 2026	Grant or award (A)	+4	$1,240.34	Form 4 (opens in a new tab)
LUCIANO JUAN R Director	19 Oct 2026	Grant or award (A)	+13	$1,240.34	Form 4 (opens in a new tab)
Fyrwald J Erik Director	19 Oct 2026	Grant or award (A)	+8	$1,240.34	Form 4 (opens in a new tab)
Alvarez Ralph Director	19 Oct 2026	Grant or award (A)	+10	$1,240.34	Form 4 (opens in a new tab)
Sulzberger Gabrielle Director	21 Sep 2026	Grant or award (A)	+4	$1,164.89	Form 4 (opens in a new tab)
LUCIANO JUAN R Director	21 Sep 2026	Grant or award (A)	+14	$1,164.89	Form 4 (opens in a new tab)
Fyrwald J Erik Director	21 Sep 2026	Grant or award (A)	+9	$1,164.89	Form 4 (opens in a new tab)
Alvarez Ralph Director	21 Sep 2026	Grant or award (A)	+11	$1,164.89	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	93,114,973	26.101%
Lilly Endowment Inc	9/30/2026	90,066,978	-0.343%
Vanguard Group Inc	12/31/2025	82,119,557	-0.189%
Vanguard Capital Management Llc	6/30/2026	65,276,117	0.235%
Pnc Financial Services Group, Inc.	6/30/2026	51,322,720	-0.012%
State Street Corp	6/30/2026	44,502,808	21.082%
Fmr Llc	6/30/2026	28,466,977	-14.238%
Geode Capital Management, Llc	6/30/2026	27,244,167	19.442%
Vanguard Portfolio Management Llc	6/30/2026	24,965,667	19.014%
Capital Research Global Investors	6/30/2026	20,873,140	-15.262%

Previous close: 1,283.66 USD
Day range: 1,261.69 – 1,279.28 USD
52-week range: 793.82 – 1,311.75 USD
Volume: 1,073,864
Market cap: $1.20T
Average volume: 3,411,384
P/E ratio: 44.9
EPS (FY 2025, diluted): 22.95 USD
Dividends (last 12 months): 6.69 USD
Dividend yield: 0.52%
Ex-dividend date: 14 Aug 2026
Shares outstanding: 941.36M
Beta (5Y monthly): 0.42

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 18:50 UTC· 11 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:12 UTC· 21 minutes ago

Dividends: Yahoo Finance dividend history (opens in a new tab) Observed 22 Oct 2026, 06:12 UTC· 21 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding. What dividend yield leaves out: dividend yield vs total return

This research is not available for LLY yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.